All In Biotech

NDA 022393 · Bristol-Myers

Istodax

Romidepsin · Intravenous

NovelAccelerated approvalOrphan

Last checked: Nov 20, 2026Latest source record: Jul 30, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2009

Nov 5, 2009

Approved uses

4

Original approval plus efficacy supplements

Registered trials

100

5 Phase 3, 3 recruiting

FAERS reports

1,689

1,456 serious, 447 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 31, 2023.

ISTODAX is indicated for the treatment of cutaneous T-cell lymphoma (CTCL) in adult patients who have received at least one prior systemic therapy. ISTODAX is a histone deacetylase (HDAC) inhibitor indicated for the treatment of cutaneous T-cell lymphoma (CTCL) in adult patients who have received at least one prior systemic therapy ( 1 ).

Mechanism: Romidepsin is a histone deacetylase (HDAC) inhibitor. HDACs catalyze the removal of acetyl groups from acetylated lysine residues in histones, resulting in the modulation of gene expression. HDACs also deacetylate non-histone proteins, such as transcription factors. In vitro, romidepsin causes the accumulation of acetylated histones, and induces cell cycle arrest and apoptosis of some cancer cell lines with IC 50 values in the nanomolar range. The mechanism of the antineoplastic effect of romidepsin observed in nonclinical and clinical studies has not been fully characterized.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 30, 2021 Supplement 17 · Efficacy OrphanLetterLabel
  • Oct 15, 2014 Supplement 13 · Efficacy LabelLetter
  • Jun 16, 2011 Supplement 4 · Efficacy · priority review Accelerated approvalLabelLetter
  • Nov 5, 2009 Original approval · Type 1 - New Molecular Entity NovelOrphanLabelReviewSummary Review
1 products under this application
  • ISTODAX · ROMIDEPSIN 10MG/VIAL · POWDER, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Romidepsin" as an intervention, any sponsor and status, largest first.

All 100 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death126
  • nausea124
  • thrombocytopenia120
  • peripheral t-cell lymphoma unspecified118
  • pyrexia105
  • drug ineffective91
  • anaemia80
  • fatigue80
  • vomiting78
  • platelet count decreased74
  • electrocardiogram qt prolonged71
  • disease progression66

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201039
201148
201267
201383
201474
2015129
2016128
201776
2018124
2019186
2020132
2021108
2022174
202368
2024113
202587
202653

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Istodax* (Romidepsin*) · HCPCS J9319

2024 spending

$25.5M

Beneficiaries

339

3,031 claims

Per beneficiary

$75,142

2024 ASP limit $30.54 per unit

View as table
YearSpending
2020$0
2021$6,417,223
2022$25,612,146
2023$27,982,716
2024$25,473,023

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 81 on PubMed

Sponsor: Bristol Myers Squibb

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.